Despite advances in defining clinically relevant subtypes of diffuse large B-cell lymphoma (DLBCL), identifying high-risk patients and improved therapeutic options remains a priority. One approach is through the identification of tumor-associated antigens (TAAs), of which cancer testis antigens (CTAs) are of particular interest. Their restricted normal tissue expression, commonly widespread expression in tumors and immunogenicity makes them attractive therapeutic targets and markers for early diagnosis of cancer. 1 We originally identified per ARNT SIM (PAS) domain containing 1 (PASD1) protein as a TAA in DLBCL 2 and acute myeloid leukemia (AML). 3 Circulating antibodies to this putative transcription factor were present in multiple high-risk DLBCL and AML patients. 2, 3 The PASD1 gene maps to chromosome Xq28, a locus containing many CTA genes, 1 and encodes two PASD1 transcripts, PASD1_v1 and PASD1_v2. In normal tissues, PASD1 mRNA was restricted to testis but its expression in DLBCL cell lines and solid tumors 2 identified PASD1 as a candidate DLBCL-associated CTA. This is significant as CTAs are infrequently expressed in B-cell non-Hodgkin's lymphomas (NHLs). 4 The aim of the current study was to raise monoclonal antibodies to investigate PASD1 protein expression in normal tissues and hematopoietic malignancies to ascertain whether PASD1 genuinely represents a CTA. Two GST-PASD1 recombinant fusion proteins incorporating aa 195-474 (common to both isoforms) and aa 540-773 (present in the longer PASD1_v2 protein only) ( Figure 1a and Supplementary Information) were used as immunogens. Preliminary enzyme-linked immunosorbent assay screening results demonstrated that antibody PASD1-1 (clone 2ALCC136) recognized the recombinant protein (aa 195-474) present in both PASD1_v1 and PASD1_v2 proteins, whereas antibody PASD1-2 (clone 2ALCC128) was specific for the recombinant protein (aa 540-773) present only in the longer PASD1_v2 protein. Immunolabeling studies (Figure 1b-d) of PASD1_v2 COS transfectants (expressing both the common region and unique C-terminal protein sequences) confirmed that both PASD1-1 and PASD1-2 antibodies were able to recognize mammalian PASD1 protein. Staining of sections from paraffinembedded pellets of PASD1_v2 transfectants (data not shown) confirmed that both antibodies recognized formalin-resistant epitopes and were suitable for the study of routinely fixed clinical material.
Immunolabeling studies using antibodies PASD1-1 and PASD1-2 on normal tonsil, lymph node, thymus, bone marrow, brain, liver, kidney, lung, pancreas, muscle, gastrointestinal tract, placenta, breast, ovary, uterus and testis confirmed PASD1 protein expression to be restricted to nuclei of a subpopulation of spermatogonia near the basal membrane in testicular tubules ( Figure 1e ). The nuclear staining pattern is consistent with the prediction of nuclear localization signals in both PASD1 isoforms ( Figure 1a ).
2 Antibody PASD1-2 also labeled a small subpopulation of salivary gland cells. This restricted normal tissue expression supports the identification of PASD1 as a CTA, specifically, a CT-X antigen encoded on the X-chromosome. 1 PASD1 protein expression, being limited to the earliest stages of spermatogenesis, is more restricted than many other CTA proteins.
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PASD1 protein expression was detected in a range of cell lines derived from hematopoietic malignancies. Variable patterns of nuclear and/or cytoplasmic labeling were observed (Figure 1f-h ). Antibody PASD1-1 gave strong membrane and cytoplasmic labeling of OCI-Ly3 (non-germinal center DLBCL-derived) cells, whereas these were unlabeled by antibody PASD1-2, suggesting the absence of PASD1_v2 in these cells. Although this latter result contrasts with our report of PASD1_v2 transcripts in this cell line, 2 disparities between mRNA and protein expression have been reported for other CTAs, for example, NY-ESO-1. 6 Such discrepancies reinforce the importance of determining relevant protein expression whenever possible. Neither antibody labeled the SUDHL-6 or SUDHL-10 (germinal center DLBCL-derived) cells suggesting PASD1 protein expression represents a potential DLBCL subtyping marker. 2 Cytoplasmic Figure 1 The detection of PASD1 protein expression in normal and malignant tissues. (a) Diagram of the PASD_v1 and PASD_v2 proteins illustrating the regions used to produce recombinant GST proteins for monoclonal antibody production (red arrows). Immunoperoxidase labeling studies show that cytocentrifuge preparations of Xpress-tagged COS transfectants expressing full-length PASD1_v2 are labeled by both (b) antibody PASD1-1 and (c) PASD1-2 (arrowed). An example of the strong punctate nuclear labeling obtained using the two antibodies can be seen in more detail from the immunofluorescent labeling shown in the inset in (c). The pattern of labeling obtained using the control anti-Xpress antibody on the PASD1 transfectants is illustrated in (d). No staining was observed in any of the vector-only controls. (e) Immunoperoxidase labeling of formalinfixed sections of human testis demonstrating PASD1 distribution was restricted to the nuclei of primary spermatogonia (arrowed). The intensity of labeling decreased on maturity, being present as nuclear dots only (inset, arrowhead) or absent in spermatogonia near to the lumen of the tubule. PASD1 protein was not detected in secondary spermatogonia, spermatids, spermatozoa, Sertoli cells or Leydig cells. Comparable patterns of labeling in testis were observed with both PASD1-1 and PASD1-2 antibodies. Immunoperoxidase labeling demonstrating heterogeneity of PASD1 expression in a range of hematological cell lines is shown in (f-h). Whereas in (f), PASD1-1 strongly labeled the membrane and cytoplasm (arrowed) of the OCI-Ly3 DLBCL cell line, no labeling was seen with antibody PASD1-2. In contrast, both antibodies demonstrated nuclear labeling of the (g) Granta519 and (h) KM-H2 cell lines. Strong cytoplasmic labeling was also observed of a subpopulation of Granta519 cells with antibody PASD1-2. Western blotting results for a variety of hematological-derived cell lines are shown in (i). Both antibodies recognize 100 kDa bands in lysates of PASD1-v2 COS cell transfectants, Thiel and KM-H2 cell lines. In contrast, antibody PASD1-1 recognized 40 kDa proteins in OCI-Ly3 and FEPD cells. No proteins were detected in either of these two cell lines by antibody PASD1-2. Loading controls are shown using an antibody to the TATA-box binding protein. Immunoperoxidase labeling in (j) illustrates PASD1 protein expression in sections from a DLBCL biopsy from a patient with immunoreactivity against PASD1. Whereas antibody PASD1-1 stained the membrane and cytoplasm of the tumor cells strongly (arrowed), weak nuclear labeling of cell nuclei was also observed in some cells. In contrast, nuclear labeling only was seen with antibody PASD1-2 (arrowhead). Immunocytochemical staining of cases of (k) mantle cell lymphoma, (l) MALT lymphoma and (m) peripheral T-cell lymphoma showing a cytoplasmic distribution of PASD1. No labeling was observed with antibody PASD1-2 (not shown).
PASD1-1 labeling was also detected in the FEPD (ALK-negative anaplastic large cell lymphoma) cell line. Nuclear labeling was seen with both antibodies in Granta519 (mantle cell lymphoma), KM-H2 (Hodgkin's lymphoma) (Figure 1g and h), K562 (chronic myeloid leukemia) cells and Thiel (multiple myeloma). 7 Western blotting studies supported the heterogeneity of PASD1 expression in cell lines (Figure 1i ). Both antibodies Letters to the Editor labeled 100 kDa proteins in lysates of PASD1_v2 COS cell transfectants, Thiel and KM-H2 cell lines suggesting that the nuclear labeling observed was that of the PASD1_v2 isoform (predicted molecular weight 87.5 kDa). Bands of 100 kDa were also detected in testis and K562 cells (not shown). In contrast, antibody PASD1-1 recognized a 40 kDa protein in OCI-Ly3 and FEPD cells. The size of this protein (smaller than PASD1_v2 or the predicted 72.5 kDa PASD1_v1), together with its cytoplasmic distribution, suggests the presence of an additional novel PASD1 isoform in these cells. Indeed, alternative splicing resulting in multiple isoforms has been previously reported with other CTAs, such as XAGE and MMA1. 1 An important factor concerning the immunotherapeutic potential of PASD1 is whether tumors from patients mounting an antibody response to PASD1 express PASD1 protein. Immunolabeling studies performed on biopsies from two patients who demonstrated PASD1 immunoreactivity 3 confirmed that their tumor cells expressed PASD1 protein (Figure 1j ). Anti-PASD1 antibodies, therefore, represent valuable reagents for identifying patients who could benefit from future PASD1-targeted therapies.
The expression of PASD1 protein in 41% (21/51 cases) of DLBCL was consistent with the frequency of reported anti-PASD1-circulating antibodies. 2 Significantly, PASD1 was also detected in a range of other B-and T-cell malignancies (Table 1) . Antibody PASD1-1 stained more tumors than antibody PASD1-2, and PASD1 expression in these tumors was predominantly cytoplasmic rather than nuclear suggesting the presence of PASD1 proteins other than PASD1_v2. Labeling intensity was variable, being strong in some tumors but weak in others. Such heterogeneity in CTA protein expression within a particular tumor category has been reported previously 6 and may be a reflection of the stage and/or proliferative state of the tumor.
It is notable that PASD1 is expressed in mantle cell lymphoma (4/9 cases), which currently has the worst prognosis among B-cell NHLs. Furthermore, some follicular lymphomas (4/15 cases) expressed PASD1, and idiotypic vaccination has already demonstrated the potential of immunotherapy in these lymphomas. 8 This is the first detailed report of the protein expression of the novel PASD1 antigen in normal tissues and a range of hematological malignancies. We have confirmed PASD1 protein to be a novel CTA that is widely expressed in lymphoma patients. This is of importance as, in contrast to the situation with solid tumors, the expression of only a small number of CTAs has been described in hematological malignancies. Future studies relating protein expression to clinico-pathological data will determine whether PASD1 expression has prognostic significance and/or a possible role in lymphoma progression. Ongoing in vitro studies of immunity to PASD1 will help to further validate this antigen as an immunotherapeutic target. Letters to the Editor
